Facebook Linkedin RSS Twitter Youtube
Home 2023

Bluebird Bio

Gene Therapy Briefs: Activist Investor Reported to Take $1B Stake in BioMarin
Drug Discovery

Gene Therapy Briefs: Activist Investor Reported to Take $1B Stake in BioMarin

Urgency Is Needed to Drive Gene Therapy and Bioprocessing
Bioprocessing

Urgency Is Needed to Drive Gene Therapy and Bioprocessing

Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases
Genome Editing

Sanofi, Scribe Launch Up-to-$1.2B Collaboration in SCD, Genomic Diseases

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy
Drug Discovery

StockWatch: Investors Shrug as FDA Weighs First Gene-Edited Therapy

ASGCT News: Hematologist David Williams Wins 2023 ASGCT Founder’s Award
Genome Editing

ASGCT News: Hematologist David Williams Wins 2023 ASGCT Founder’s Award

Gene Therapy Imperative Optimizes Manufacturing to Keep Pace with Market Development
Bioprocessing

Gene Therapy Imperative Optimizes Manufacturing to Keep Pace with Market Development

Prime-Edited Patient Blood Stem Cells Fully Engraft and Rescue Sickle Cell Mice
Genome Editing

Prime-Edited Patient Blood Stem Cells Fully Engraft and Rescue Sickle Cell Mice

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron
GEN Edge

StockWatch: COPD Data, Analysts, Treg Cell Therapy Deal Lift Regeneron

Seven Biopharma Trends to Watch in 2023
A-Lists

Seven Biopharma Trends to Watch in 2023

StockWatch: After Bluebird’s Second Approval, Investors Are Looking for More
GEN Edge

StockWatch: After Bluebird’s Second Approval, Investors Are Looking for More

123Page 1 of 3
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.